SPA70 is a potent antagonist of human pregnane X receptor

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Lin, Wenwei ^a   Wang, Yue Ming ^a   Chai, Sergio C ^a   Lv, Lili ^b   Zheng, Jie ^c   Wu, Jing ^a   Zhang, Qijun ^b   Wang, Yong Dong ^a   Griffin, Patrick R ^c   Chen, Taosheng ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Shanghai Medicilon Inc   (China)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION FUNCTION 2; HORMONE RECEPTOR STIMULATING AGENT; METHYL GROUP; MIDAZOLAM; PACLITAXEL; PREGNANE X RECEPTOR; PREGNANE X RECEPTOR ANTAGONIST; PROTEIN; PROTEIN INHIBITOR; RIFAMPICIN; SJB 7; SPA 70; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; HORMONE ANTAGONIST; STEROID RECEPTOR;

CANCER; CELLS AND CELL COMPONENTS; DRUG; DRUG RESISTANCE; ENZYME; ENZYME ACTIVITY; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY ASSAY; DEUTERIUM HYDROGEN EXCHANGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; IC50; LIGAND BINDING; LIVER CELL; MALE; MAXIMUM TOLERATED DOSE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG RESISTANCE; HEK293 CELL LINE; MOLECULAR MODEL; TRANSGENIC MOUSE;

ANIMALS; CELL LINE; DRUG RESISTANCE; HEK293 CELLS; HORMONE ANTAGONISTS; HUMANS; MICE, TRANSGENIC; MODELS, MOLECULAR; RECEPTORS, STEROID;

EID: 85030324563     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00780-5     Document Type: Article

References (62)

1. Bertilsson, G. et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 95, 12208-12213 (1998).
2. Kliewer, S. A. et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92,73-82 (1998).
3. Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023 (1998).
4. Wang, Y. M., Ong, S. S., Chai, S. C. & Chen, T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8, 803-817 (2012).
5. Chai, S. C., Cherian, M. T., Wang, Y. M. & Chen, T. Small-molecule modulators of PXR and CAR. Biochim. Biophys. Acta 1859, 1141-1154 (2016).
6. Kortagere, S., Krasowski, M. D. & Ekins, S. Ligand- and structure-based pregnane X receptor models. Methods Mol. Biol. 929, 359-375 (2012).
7. Banerjee, M., Robbins, D. & Chen, T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov. Today 20, 618-628 (2015).
8. Chai, X., Zeng, S. & Xie, W. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin. Drug Metab. Toxicol. 9, 253-266 (2013).
9. Gotoh, S. & Negishi, M. Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis. Sci. Rep. 5, 14076 (2015).
10. Sinz, M. W. Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development. Drug Metab. Rev. 45,3-14 (2013).
11. Wang, Y. M., Chai, S. C., Brewer, C. T. & Chen, T. Pregnane X receptor and drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 10, 1521-1532 (2014).
12. Oladimeji, P., Cui, H., Zhang, C. & Chen, T. Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk. Expert Opin. Drug Metab. Toxicol. 12, 997-1010 (2016).
13. Ma, X. et al. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35, 194-200 (2007).
14. Xie, W. et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 435-439 (2000).
15. Kodama, S. & Negishi, M. PXR cross-talks with internal and external signals in physiological and pathophysiological responses. Drug Metab. Rev. 45, 300-310 (2013).
16. Guo, G. L. et al. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol. Sci. 82, 374-380 (2004).
17. Li, F. et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat. Med. 19, 418 (2013).
18. Mani, S., Dou, W. & Redinbo, M. R. PXR antagonists and implication in drug metabolism. Drug Metab. Rev. 45,60-72 (2013).
19. Chen, T. Overcoming drug resistance by regulating nuclear receptors. Adv. Drug Deliv. Rev. 62, 1257-1264 (2010).
20. Carnahan, V. E. & Redinbo, M. R. Structure and function of the human nuclear xenobiotic receptor PXR. Curr. Drug Metab. 6, 357-367 (2005).
21. Delfosse, V. et al. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds. Nat. Commun. 6, 8089 (2015).
22. Ekins, S. et al. Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput. Biol. 5, e1000594 (2009).
23. Watkins, R. E., Davis-Searles, P. R., Lambert, M. H. & Redinbo, M. R. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331, 815-828 (2003).
24. Poulton, E. J. et al. Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol. Appl. Pharm. 266, 122-131 (2013).
25. Wang, H. W. et al. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res. 13, 2488-2495 (2007).
26. Fuchs, I. et al. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur. J. Clin. Pharmacol. 69, 507-513 (2013).
27. Lin, W. et al. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J. Biol. Chem. 283, 30650-30657 (2008).
28. Sevrioukova, I. F. & Poulos, T. L. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc. Natl Acad. Sci. USA 114, 486-491 (2017).
29. Thummel, K. E. & Wilkinson, G. R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
30. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. & Collins, J. M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
31. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
32. Wiese, R. J., Uhland-Smith, A., Ross, T. K., Prahl, J. M. & DeLuca, H. F. Up- regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J. Biol. Chem. 267, 20082-20086 (1992).
33. Genini, D. & Catapano, C. V. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity. J. Biol. Chem. 282, 11776-11785 (2007).
34. Wang, Y. M. et al. Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol. Appl. Pharmacol. 272,96-107 (2013).
35. Wang, Y. M. et al. Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo. Biochem. Pharmacol. 96, 357-368 (2015).
36. Wang, W. et al. Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. Protein Eng. Des. Sel. 21, 425-433 (2008).
37. Watkins, R. E. et al. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 292, 2329-2333 (2001).
38. Noble, S. M. et al. Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 45, 8579-8589 (2006).
39. Banerjee, M., Chai, S. C., Wu, J., Robbins, D. & Chen, T. Tryptophan 299 is a conserved residue of human pregnane X receptor critical for the functional consequence of ligand binding. Biochem. Pharmacol. 104, 131-138 (2016).
40. Ngan, C. H. et al. The structural basis of pregnane X receptor binding promiscuity. Biochemistry 48, 11572-11581 (2009).
41. Chalmers, M. J. et al. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 78, 1005-1014 (2006).
42. Sakamaki, Y., Inaba, Y., Yoshimoto, N. & Yamamoto, K. Potent antagonist for the vitamin D receptor: vitamin D analogues with simple side chain structure. J. Med. Chem. 53, 5813-5826 (2010).
43. Yoshimoto, N. et al. Butyl pocket formation in the vitamin D receptor strongly affects the agonistic or antagonistic behavior of ligands. J. Med. Chem. 55, 4373-4381 (2012).
44. Lin, W., Yang, L., Chai, S. C., Lu, Y. & Chen, T. Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor. Eur. J. Med. Chem. 108, 505-528 (2016).
45. Pokhodylo, N. T., Matiychuk, V. S. & Obushak, M. (Arylsulfonyl)acetones and -acetonitriles: new activated methylenic building blocks for synthesis of 1,2,3-Triazoles. Synthesis (Mass) 14, 2321-2323 (2009).
46. Aalten, H. L. et al. The copper catalysed reaction of sodium methoxide with aryl bromides. A mechanistic study leading to a facile synthesis of anisole derivatives. Tetrahedron 45, 5565-5578 (1989).
47. Lin, W. et al. Development of BODIPY FL vindoline as a novel and high-affinity pregnane X receptor fluorescent probe. Bioconjug. Chem. 25, 1664-1677 (2014).
48. Li, G. et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol. Appl. Pharmacol. 258, 268-274 (2012).
49. Yu, D. D., Lin, W., Forman, B. M. & Chen, T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg. Med. Chem. 22, 2919-2938 (2014).
50. Cherian, M. T., Lin, W., Wu, J. & Chen, T. CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor. Mol. Pharmacol. 87, 878-889 (2015).
51. Schuetz, E. G., Schinkel, A. H., Relling, M. V. & Schuetz, J. D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl Acad. Sci. USA 93, 4001-4005 (1996).
52. Liu, L., Wang, Y. D., Wu, J., Cui, J. & Chen, T. Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells. BMC Cancer 12, 154 (2012).
53. Schuetz, E. et al. Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol. Pharmacol. 62, 439-445 (2002).
54. Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene. Ther. 6, 1258-1266 (1999).
55. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
56. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
57. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
58. Cherian, M. T., Yang, L., Chai, S. C., Lin, W. & Chen, T. Identification and characterization of CINPA1 metabolites facilitates structure-activity studies of the constitutive androstane receptor. Drug Metab. Dispos. 44, 1759-1770 (2016).
59. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
60. Cummins, D. J. et al. Two-site evaluation of the repeatability and precision of an automated dual-column hydrogen/deuterium exchange mass spectrometry platform. Anal. Chem. 88, 6607-6614 (2016).
61. Pascal, B. D. et al. HDX workbench: software for the analysis of H/D exchange MS data. J. Am. Soc. Mass Spectrom. 23, 1512-1521 (2012).
62. Keppel, T. R. & Weis, D. D. Mapping residual structure in intrinsically disordered proteins at residue resolution using millisecond hydrogen/ deuterium exchange and residue averaging. J. Am. Soc. Mass Spectrom. 26, 547-554 (2015).